Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury
A legfontosabb adatok
- Ki végzi
- Medstar Health Research Institute
- Hol
- Washington D.C. (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 182 fő vett részt
- Kezdés
- 2020. jún. 1.
- Befejezés
- 2025. febr. 14.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Culturelle 10 Billion CFU Capsule (2 doses)
- Culturelle 10 Billion CFU Capsule (4 doses)
- A regiszteradat frissítve
- 2026. november 3.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter összes feltétele (11)A regiszter feltételeinek elrejtése
Ki vehet részt
- SCI at least 1-year duration
- Neurogenic bladder
- Utilizing intermittent catheterization for bladder management
- Women must be premenopausal and not currently menstruating
- Community dwelling
Ki nem vehet részt
- Sexual activity within the previous 72 hours
- Psychologic or psychiatric conditions influencing the ability to follow instructions
- Use of prophylactic antibiotics
- Instillation of intravesical antimicrobials to prevent UTI
- Use of oral or IV antibiotics within the past 2 weeks
- Participation in another study with which results could be confounded
Helyszínek itt: Egyesült Államok
- MedStar National Rehabilitation HospitalWashington D.C., Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
A vizsgálat 2 csoportja
- Low Dosage GroupA vizsgált kezelés
For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 2 LGG capsules and will repeat this process the following day ("Low" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion.
Kezelés: Culturelle 10 Billion CFU Capsule (2 doses)
- High Dosage GroupA vizsgált kezelés
For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses ("High" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion.
Kezelés: Culturelle 10 Billion CFU Capsule (4 doses)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2026. november 3.